Pharmacology and pharmacokinetics of imatinib in pediatric patients

M Suttorp, M Bornhäuser, M Metzler… - Expert Review of …, 2018 - Taylor & Francis
Introduction: The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target
BCR-ABL1 which is constitutively activated in chronic myeloid leukemia (CML). Following …
被引用次数：52 相关文章

Pharmacology and pharmacokinetics of imatinib in pediatric patients

M Suttorp, M Bornhäuser, M Metzler… - Expert review of …, 2018 - pubmed.ncbi.nlm.nih.gov
The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target BCR-ABL1
which is constitutively activated in chronic myeloid leukemia (CML). Following the …

Pharmacology and pharmacokinetics of imatinib in pediatric patients.

M Suttorp, M Bornhäuser, M Metzler… - Expert Review of …, 2017 - europepmc.org
The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target BCR-ABL1
which is constitutively activated in chronic myeloid leukemia (CML). Following the …